Option chain shows key data for MediPharm Labs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for MediPharm Labs.

MediPharm Labs (OTC:MEDIF) Stock, Option Chain

MediPharm Labs

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

pepi-stojanovski-MJSFNZ8BAXw-unsplash(1)

Cannabis

Earnings

News

MEDIF

TSX:LABS

CBD-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday its third quarter financial results for the three months ended Sept. 30, 2024.&#34;Q3 2024 was a major step in the right direction towards profitability,&#34; Greg Hunter, the company&#39;s CFO, said. &#34;Paying off our debt and rationalizing facilities, pursuing cost efficiencies while growing our higher margin international revenues are all critical elements to position us for long-term sustainable growth.&#34;

CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth

elsa-olofsson-FkfIPqqv2Oc-unsplash(19)

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). &#34;We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability,&#34; David Pidduck, the company&#39;s CEO, said. &#34;The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats.&#34;

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

finance and marijuana (Kindel Media by Pexels)(22)

Exclusives

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CSE:VEXT

TSX:XLY

VEXTF

Select Sector SPDR-Consumer Discretionary

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, Aug. 20, 2024. A conference call and webcast will take place on the same day at 08:00 am Eastern Time. Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) will report earnings results for its second quarter ended June 30, 2024, on Thursday, Aug. 15, 2024, before the financial markets open.Cannabinoids-focused MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, Aug. 14, 2024. A conference call and audio webcast will take place the same day at 8:30 am Eastern Time.

This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now

MEDIPHARM LABS CORP by Medipharm Labs Corporation

MediPharm Labs Corp

Medifast Inc

Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) reported quarterly losses of $(1.12) per share. This is a 12.5 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $2.06 billion which beat the analyst consensus estimate of $1.91 billion by 7.98 percent. This is a 12.80 percent increase over sales of $1.82 billion the same period last year.

BZUN

Baozun Q3 2024 GAAP EPS RMB(1.12) Up From RMB(1.28) YoY, Sales RMB2.06B Beat RMB1.91B Estimate

Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) reported quarterly losses of $(0.86) per share. This is a 10650 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $12.35 million in sales this quarter. This is a 37.92 percent decrease over sales of $19.90 million the same period last year.

Yunji Q3 EPS $(0.86) Down From $(0.01) YoY, Sales $12.35M Down From $19.90M YoY

Subsea 7 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SUBCY#OTC">SUBCY</a>) reported quarterly earnings of $0.31 per share. This is a 181.82 percent increase over earnings of $0.11 per share from the same period last year. The company reported $1.83 billion in sales this quarter. This is a 16.22 percent increase over sales of $1.58 billion the same period last year.

SUBCY

Subsea 7 Q3 EPS $0.31 Up From $0.11 YoY, Sales $1.83B Up From $1.58B YoY

<ul>
<li>In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310's potential to deliver localized therapeutic effects while minimizing systemic exposure. Additionally, all patients tolerated LP-310 without significant adverse reactions.</li>
<li>Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to advance to the next stage of the trial, which will evaluate a higher dose of 0.5 mg of LP-310.</li>
</ul>

Biotech

Health Care

General

LIPO

Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025

KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.57 by 2.55 percent. The company reported quarterly sales of $22.58 billion which missed the analyst consensus estimate of $23.46 billion by 3.74 percent. This is a 825.16 percent increase over sales of $2.44 billion the same period last year.

BEKE

KE Holdings Q3 2024 Adj EPADS RMB1.53 Misses RMB1.57 Estimate, Sales RMB22.58B Miss RMB23.46B Estimate

TD Cowen analyst Andrew Charles reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $50 price target.

Price Target

Reiteration

Analyst Ratings

JACK

TD Cowen Reiterates Hold on Jack In The Box, Maintains $50 Price Target

Needham analyst Bernie McTernan maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $200 to $235.

Needham Maintains Buy on Wix.com, Raises Price Target to $235

Delta Air Lines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NASDAQ">DAL</a>) CEO Ed Bastian has suggested that President-elect Donald Trump&#8216;s administration could provide a &#8220;breath of fresh air&#8221; for the airline industry, criticizing what he perceives as government &#8220;overreach&#8221; during President Joe Biden&#8216;s era.
What Happened: Speaking ahead of the company&#8217;s investor day, Bastian signaled potential regulatory changes that could significantly impact the aviation sector, <a href="https://apnews.com/article/delta-airlines-trump-biden-regulation-c4393d5f763d95c8286d4069563032dc#">reported</a> the Associated Press on Thursday.
The airline executive&#8217;s comments reflect a broader sentiment among industry leaders who anticipate a more business-friendly regulatory environment. 
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) CEO Robert Jordan similarly expressed hope for a Department of Transportation that might be &#8220;less aggressive&#8221; in rule-making, highlighting growing frustration with current consumer protection regulations.
See Also: <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">Bitcoin Hits $95K For The First Time Ever, Ethereum, Dogecoin Flat As Trump&#8217;s Crypto Policy Takes Shape</a>
Delta&#8217;s financial performance provides context for these expectations. The airline reported a robust $2.6 billion profit in the first nine months of 2024, with projected fourth-quarter adjusted profit between $1.60 and $1.85 per share. The company expects 2025 revenue growth in mid-single digits, positioning itself strongly amid potential regulatory shifts.
Why It Matters: Wall Street appears cautiously optimistic about <a href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector">the airline sector&#8217;s future</a>. Goldman Sachs has resumed coverage of major airlines, providing Delta with a &#8220;Buy&#8221; rating and an $83 price target. Analysts expect continued supply constraints through 2025, with a focus on airlines&#8217; ability to adapt to changing market conditions.
The potential appointment of Sean Duffy as Transportation Secretary could herald broader changes across the transportation sector. Industry <a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads">observers speculate about the potential streamlining of regulations</a>, enhanced infrastructure focus, and possible modifications to electric vehicle and autonomous driving policies.
Price Action: Delta Air Lines closed at $63.64 on Wednesday, down 1.71% for the day. In pre-market trading, the stock was down 0.5% at the time of writing. Year to date, the stock has surged by 57.33%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/42044634/653125">Dave Ramsey Recalls The Day American Express Called His Wife, Asking Why Stay &#8216;With A Man That Won&#8217;t Pay His Bills.&#8217; Here&#8217;s What He Did Next</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

Delta Chief Says Trump Could Be A 'Breath Of Fresh Air' For Aviation Industry

William Blair analyst Dylan Carden downgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Outperform to Market Perform.

Downgrades

ULTA

William Blair Downgrades Ulta Beauty to Market Perform

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) released their September quarter results just a day apart. Target&#8217;s management highlighted that its customers were most active during sales and promotional events, while Walmart&#8217;s leadership attributed 75% of its market share growth to households earning six-figure incomes.
Target&#8217;s executive vice president and chief commercial officer company Rick Gomez said that their consumers &#8220;know there are deals to be found, they&#8217;re willing to wait for sales and willing to search across multiple retailers.&#8221; While the latter&#8217;s chief executive officer, Doug McMillon attributed <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">75% of their market share gains</a> to "households earning more than $100,000."
Also read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart Market Share Surges As Six-Figure Income Households Drive 75% Of Growth In Q3: &#8216;People Come To Us To Shop As A Primary Destination&#8217;</a>
What Happened: Gomez highlighted that Target&#8217;s consumers were looking for promotions with an example. &#8220;Our Target Circle week this quarter was one of our biggest yet. However, we saw a more pronounced sales dip both the week before and the week after the event, showing just how planful consumers are in seeking out promotions when they shop.&#8221;
&#8220;Similarly, we saw consumers lean into everyday essential stock-up promotions throughout the quarter to further stretch their monthly budgets. We saw a strong reaction to promotions throughout the quarter,&#8221; he added.
On the flip side, John David Rainey the chief financial officer of Walmart re-affirmed his CEO&#8217;s view and said, &#8220;we're seeing higher engagement across income cohorts with upper-income households continuing to account for the majority of our share gains.&#8221;
Why It Matters: Shares of Target Corporation plunged by 21.41% to close at $121.72 apiece, on Wednesday, as compared to a 0.16% advance in the NYSE Composite Index. <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target&#8217;s third-quarter</a> adjusted earnings per share of $1.85, missed the street view of $2.30. Quarterly total revenue of $25.67 billion (+1.1% year over year) missed the analyst consensus estimate of $25.90 billion.
Brian Cornell, chair and chief executive officer of Target said, "We encountered some unique challenges and cost pressures that impacted our bottom-line performance.&#8221; The third-quarter gross margin rate decreased by 0.2 percentage points to 27.2%.
Also read: <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks</a>
On Tuesday, <a href="https://www.benzinga.com/pressreleases/24/11/b42058916/walmart-reports-strong-revenue-growth-of-5-5-with-operating-income-growing-faster-at-8-2">Walmart&#8217;s third-quarter results</a> beat estimates and the fiscal 2025 guidance was raised. Its shares rose 3% on Tuesday, while it was further up by 0.67% to $87.18 apiece as per Wednesday&#8217;s close.
Walmart&#8217;s ales were at $169.59 billion, up 5.5% year over year or 6.2% (at constant currency), beating the consensus of $167.72 billion. The gross margin rate was up 21 bps to 24.2% aided by improvement in the Walmart U.S. Operating income was up by $0.5 billion or 8.2% year over year at $6.7 billion.
Price Action: On a year-to-date basis, Walmart has surged by 64.19%, while Target is down by 14.94%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The NYSE Composite Index was up 17.26% in the same period. In Thursday&#8217;s premarket, TGT shares were up 0.5%. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="272" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png" alt="" class="wp-image-658433" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-300x80.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-768x204.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1536x408.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT.png 1741w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Flickr/ Mike Mozart

Earnings Beats

Earnings Misses

Target Says Shoppers Wait For 'Deals' A Day After Rival Walmart Credits Market Gains To Wealthy Households: TGT Edges Up Marginally In Thursday Premarket

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintains the price target from $4 to $4.

Upgrades

SAGE

RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4

Piper Sandler analyst Brent Bracelin reiterates Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $165 to $185.

SNOW

Piper Sandler Reiterates Overweight on Snowflake, Raises Price Target to $185

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) new vehicle registrations in the EU are continuing to drop, <a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown">threatening the company&#8217;s global EV delivery target</a> for the year.
What Happened: Tesla had 11,088 vehicle registrations in the European Union in October, marking a drop of 21% from the corresponding period last year, according to data from the European Automobile Manufacturers' Association (ACEA). 
This is despite battery electric vehicle registrations rising 2.4% in the EU last month to 124,907 units on the back of growing popularity in Denmark and the Netherlands. 
Tesla had 192,661 new vehicle registrations in the EU from January through the end of October, marking a drop of over 11% year-on-year. 
For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an ambitious target.
Why It Matters: In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
According to Tesla researcher Troy Teslike, the low sales in Europe are likely to impact Tesla&#8217;s aim to prevent a drop in yearly deliveries. 
&#8220;Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are down too,&#8221; <a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher">Teslike said</a> in a post on X earlier this week.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are… <a href="https://t.co/fflyf175xp">https://t.co/fflyf175xp</a>
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1858430634315943990?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Tesla stock fell 1.2% on Wednesday to close at $342.03, and declined over 1% in premarket trading on Thursday. Year-to-date, the stock is up 37.7%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways" target="_blank" rel="noreferrer noopener">Jim Cramer Thinks Trump's Plans For Robotaxis Are ‘Fanciful,' But He Is Still Bullish On Tesla Stock: ‘The Musk Premium Will Work Its Magic In Other Ways'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target

Macquarie analyst Austin Yun upgrades Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) from Underperform to Neutral and announces $13.5 price target.

Macquarie Upgrades Piedmont Lithium to Neutral, Announces $13.5 Price Target

<ul>
<li>Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029.&nbsp;</li>
<li>The company remains on track to deliver core operating income margin1 of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements.</li>
<li>"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms. Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Vas Narasimhan, CEO of Novartis. "Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029. Taken together, we remain confident in our focused strategy and ability to deliver sustainable value creation for shareholders."</li>
</ul>

Large Cap

Guidance

Novartis Upgrades Its Mid-term Guidance. Previous Guidance For +5% Sales CAGR 2023-2028 Was Upgraded To +6%, Driven By Strong Momentum Of In-market Growth Drivers And Upcoming Launches, Most Of Which Have Expected US Exclusivity In 2030's Or Beyond

HSBC analyst Carlos Gomez-Lopez initiates coverage on Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Buy rating and announces Price Target of $33.

Initiation

HSBC Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $33

The Offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company estimates that the net proceeds from the sale of the Notes, after deducting initial purchaser discounts but before deducting the other estimated expenses of the offering, will be approximately US$124.2 million (or approximately US$143.5 million if the initial purchasers exercise their option to purchase additional Notes in full). The Company intends to use the net proceeds from the Offering (including any net proceeds from the sale of any additional Notes that may be sold should the initial purchasers exercise their option to purchase additional Notes) for the construction of copper-gold mining projects outside of China, for the exploration and development of other projects and for working capital.

Silvercorp Metals Prices $130M 4.75% Convertible Senior Notes Due 2029

Investment supports continued expansion of AI and business intelligence capabilities for over 70,000 hospitality properties globally
Lighthouse, the leading commercial intelligence platform for the travel &amp; hospitality industry, today announced an approximately $370 million growth investment led by global investment firm, KKR. This investment accelerates Lighthouse's mission to reimagine commercial strategy for the $15 billion travel &amp; hospitality technology market. Proceeds from the investment will be used to drive continued product innovation across Lighthouse's platform, strategic acquisitions, and global expansion efforts.

KKR Backs Lighthouse With $370M To Redefine Hospitality Market Strategy With AI Tools

BTIG analyst Andrew Harte maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $290 to $570.

MSTR

BTIG Maintains Buy on MicroStrategy, Raises Price Target to $570

Geothermal has been overlooked as a key renewable energy source, says IGA and Seequent

Bentley's Seequent Partners With IGA To Unlock Geothermal Energy's Potential For A Sustainable Future

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MediPharm Labs (OTCMKTS:<a href="https://investorplace.com/stock-quotes/medif-stock-quote/">MEDIF</a>) just reported results for the second quarter of 2024.<ul><li>MediPharm Labs reported earnings per share of -1 cent.</li><li>The company reported revenue of $7.57 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/medif-stock-earnings-medipharm-labs-for-q2-of-2024/">MEDIF Stock Earnings: MediPharm Labs Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MEDIF Stock Earnings: MediPharm Labs Reported Results for Q2 2024

MediPharm Labs goes debt-free

MediPharm Labs (TSE:LABS) has released an update. MediPharm Labs Corp., a pharmaceutical company specializing in cannabis-based health products, ha...

MediPharm Labs Achieves Debt-Free Milestone

MediPharm Labs (TSE:LABS) has released an update. MediPharm Labs announces the departure of President and Co-Founder Keith Strachan, who will trans...

MediPharm Labs Leadership Transition and Future Focus

MediPharm Labs (TSE:LABS) has released an update. MediPharm Labs, a leading pharmaceutical company specializing in cannabinoid products, is set to ...

MediPharm Labs to Announce Q3 2024 Results

MediPharm Labs reports Q3 results

MediPharm Labs (TSE:LABS) has released an update. MediPharm Labs reported a significant improvement in its financial results for the third quarter,...

MediPharm Labs Reports Financial Growth and Expansion

MediPharm Labs (TSE:LABS) has released an update. MediPharm Labs reported a notable increase in its third-quarter net revenue, driven by a strong 3...

MediPharm Labs Shows Strong Q3 Growth

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, a Phase 3 ...

Rising High: Cannabis firms report quarterly earnings

Medipharm Labs (Otc) ( ($MEDIF) ) has released its Q3 earnings. Here is a breakdown of the information Medipharm Labs (Otc) presented to its invest...

Comments

MediPharm Labs

MediPharm Labs (MEDIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga